GLP-1s: Where’s your health system?

GLP-1s: Where’s your health system?

The blockbuster drug class of GLP-1s raises big questions for how obesity and obesity-related disease affects health systems. Becker's is seeking more information about health system leaders' focus, experience and work with GLP-1s and strategy with the following survey:
Email*
Name*

First NameLast Name
Job Title*
Organization Name*
source
How has the introduction of GLP-1 medications influenced your organization's approach to weight management and diabetes care?*
What challenges has your organization faced in integrating GLP-1 medications into care protocols? (Select all that apply)*

Cost and reimbursement issuesPatient adherenceProvider education and trainingSupply chain constraintsRegulatory and approval processes
On a scale of 1 to 5, how significant do you believe GLP-1 medications will be in managing obesity and diabetes over the next five years?*

1

2

3

4

5

1 is Highly Insignificant, 5 is Highly Significant
How are you preparing your organization to handle the potential increase in demand for GLP-1 medications?*
How has the availability of GLP-1s affected your organization's partnerships with pharmaceutical companies?*

Strengthened partnershipsNo changeWeakened partnershipsNot applicable
Rank the following areas where you expect GLP-1s to have the most impact:*
Has your organization conducted any internal studies or assessments on the long-term effects of GLP-1 medications?*

YesNo
utm_campaign
utm_source
Should be Empty: